Potential Anti-Fibrotic Oral Treatment Shows Promise in Early Studies, Redx Announces

This topic contains 0 replies, has 1 voice, and was last updated by  Pulmonary Fibrosis News Moderator 9 months, 1 week ago.

  • Author
  • #15647

    RXC006, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF) and other types of fibrosis, was seen to ease lung scarring in a mouse model of IPF, its developer, Redx Pharma, has announced.

    The investigative inhibitor is also reported to work favorably in human lung fibroblasts grown in the laboratory. Based on these results, Redx Pharma plans to start clinical trials testing RXC006 in 2020. Click here to read more.

    Are you interested in updates on this research?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?


Create Account